CME Presentations

Bladder Cancer

Presentations

Speakers

  • Neal D. Shore, MD, FACS

    Neal D. Shore, MD, FACS

    Neal D. Shore, MD, FACS

    Medical Director, CPI

    Neal Shore, MD, is the Medical Director for the Carolina Urologic Research Center and practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina. Dr. Shore has conducted more than 400 clinical trials, focusing on GU Oncology indications. He is the Chief Medical Officer, Surgery/Urology, for GenesisCare,US. Dr. Shore serves on the SITC Guidelines Committee for Bladder Cancer and the boards of the Bladder Cancer Advocacy Network and the Duke Global Health Institute. He is the Chair of the LUGPA Education Committee. Dr. Shore is on the editorial boards of Reviews in Urology, Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE, Urology Practice, World Journal of Urology, and serves as Editor for Everyday Urology-Oncology. Also, he’s a Fellow of the American College of Surgeons.

    Session Appearances

    Refining Risk-Based Treatment Decisions in the Era of Kidney-Sparing Options for Upper Tract Urothelial Carcinoma

    Second-line Therapy and Beyond for Progressive UC

    Addressing Real-World Challenges of Integrating Novel Therapies for Patients with Upper Tract Urothelial Carcinoma

    Redefining the ‘Best’ Treatment Option for Patients with UTUC

    Refining the First-Line and Maintenance Therapy Approach for Advanced/Metastatic UC

    A Stratified Approach to Managing NMIBC with Surgical vs Non-Surgical Options

  • John Gore, MD, MS, FACS

    John Gore, MD, MS, FACS

    John Gore, MD, MS, FACS

    Professor in Urology

    John Gore, MD, MS, FACS is a urologic oncologist and health services researcher. Dr. Gore is a Professor in Urology, Adjunct Professor in Surgery at the University of Washington, and Affiliate Investigator at the Fred Hutchinson Cancer Research Center. He is the Program Director of the UW SUO Fellowship in Urologic Oncology and has served as the primary mentor on 13 extramural mentored research awards including from the Urology Care Foundation, DOD, ASCO Conquer Cancer Foundation, Bladder Cancer Advocacy Network, and NIH. Dr. Gore is pursuing a translational health services and patient-centered outcomes research program toward improving access to care, quality of life, and quality of care for urologic cancers. He has active funding from PCORI, NIH, American Cancer Society, and DOD.

    Session Appearances

    Redefining the ‘Best’ Treatment Option for Patients with UTUC

  • Joshua Meeks, MD, PhD

    Joshua Meeks, MD, PhD

    Joshua Meeks, MD, PhD

    Associate Professor of Urology, Biochemistry and Molecular Genetics

    Joshua Meeks, MD, PhD, is an Associate Professor of Urology, Biochemistry and Molecular Genetics at Northwestern University Feinberg School of Medicine, as well as Section Chief of Robotic Surgery at the Jesse Brown VA Medical Center. He is a urologic surgeon with expertise in the diagnosis, treatment and management of bladder cancer. Dr. Meek’s research interests focus on the epigenetics and genetic mutations associated with cancer biology, specifically on how chromatin remodeling genes play a role in bladder cancer. In 2019, Dr. Meeks was the National Surgery Office VHA Chair of the Urology Surgical Advisory Board and on the Society of Urologic Oncology Fall Meeting Bladder Planning Committee. Currently, he serves on the Editorial Board of the Journal Surgical Oncology.

    Session Appearances

    A Stratified Approach to Managing NMIBC with Surgical vs Non-Surgical Options

  • Matthew Galsky, MD

    Matthew Galsky, MD

    Matthew Galsky, MD

    Director of Genitourinary Medical Oncology

    Matthew Galsky, MD, is the director of genitourinary medical oncology at the Mount Sinai School of Medicine Tisch Cancer Institute in New York. Dr Galsky specializes in caring for patients with genitourinary malignancies (bladder, prostate, kidney, and testicular cancers). His research focuses on the clinical development of novel therapies for genitourinary cancers, with a particular emphasis on bladder cancer, and he regularly speaks nationally and internationally on the topic. His research has been published in numerous journals, including the Journal of Clinical Oncology, Journal of the National Cancer Institute, Lancet Oncology and Lancet, and has been funded by organizations that include the National Institutes of Health/National Cancer Institute and the Department of Defense.

    Session Appearances

    Refining the First-Line and Maintenance Therapy Approach for Advanced/Metastatic UC

  • Arjun Balar, MD

    Arjun Balar, MD

    Arjun Balar, MD

    Director of the Genitoruinary Medical Oncology Program

    Arjun V. Balar, MD, is the Director of the Genitoruinary Medical Oncology Program at the Perlmutter Cancer Center at New York University (NYU) Langone Health and an Assistant Professor at NYU School of Medicine. Dr. Balar’s research focuses on bladder cancer and immunotherapy as well as molecularly targeted therapy. His main research focal point is on novel immunotherapies and combinations with the goal of identifying better tolerated and more effective therapies in advanced urothelial cancer; as such, clinical trial findings from Dr. Balar led to accelerated FDA approval of two drugs for advanced bladder cancer. Furthermore, Dr. Balar works closely with surgeons and radiation oncologists to enhance multidisciplinary care models and with basic scientists to foster traditional research.

    Session Appearances

    Second-line Therapy and Beyond for Progressive UC

CME Information

Paradigm Shifts and Point-of-Care Decisions for Better Control of Urothelial Carcinoma/Bladder Cancer

Jointly provided by Postgraduate Institute for Medicine (PIM) and PlatformQ Health Education, LLC (PQHE) working in collaboration with the Large Urology Group Practice Association (LUGPA).

ACKNOWLEDGEMENT

This activity is supported by educational grants from Merck; Astellas and Seagen Inc.; and UroGen Pharma, Inc.

TUITION

Complimentary

JointlyAccreditedProvider Logo

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

LIVE CREDIT DESIGNATION STATEMENTS

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this live activity for a maximum of 4.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ENDURING CREDIT DESIGNATION STATEMENTS

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 4.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DATE OF RELEASE/EXPIRATION

Live Activity

Thursday, October 7, 2021:
  • 12:30pm – 1:30pm ET: Redefining the ‘Best’ Treatment Option for Patients with UTUC
  • 1:30pm – 2:30pm ET: A Stratified Approach to Managing NMIBC with Surgical vs Non-Surgical Options
  • 3:00pm – 4:00pm ET: Refining the First-Line and Maintenance Therapy Approach for Advanced/Metastatic UC
  • 4:00pm – 5:00pm ET: Second-Line Therapy and Beyond for Progressive UC

Enduring Material

The enduring material will be available from October 7, 2021 to October 7, 2022

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

Redefining the ‘Best’ Treatment Option for Patients with UTUC
  • Explain how to use histology to identify low-grade vs high-grade UTUC
  • Critique the implications of kidney-sparing treatment in patients with low-grade UTUC
  • Appraise recent safety and efficacy data for emerging and current therapies for UTUC
A Stratified Approach to Managing NMIBC with Surgical vs Non-Surgical Options
  • Assess recent safety and efficacy data for current and emerging adjuvant therapies for low-grade NMIBC
  • Delineate the risks and benefits of low- vs high-intensity cystoscopic surveillance in patients with high-risk NMIBC
  • Evaluate clinical-trial data for new and investigational agents in the management of patients with high-risk NMIBC
Refining the First-Line and Maintenance Therapy Approach for Advanced/Metastatic UC
  • Compare and contrast first-line therapy options for the management of advanced/metastatic UC
  • Discuss the role of immunotherapy as maintenance therapy following platinum treatment in patients with advanced/metastatic UC
Second-Line Therapy and Beyond for Progressive UC
  • Outline clinical/disease characteristics that can guide treatment selection in the second-line setting and beyond for patients with advanced UC
  • Discuss clinical-trial efficacy and safety data for emerging agents that target disease progression in patients with advanced UC

TARGET AUDIENCE

This activity is intended for genitourinary and medical oncologists, urologists, oncology advanced practice providers, oncology nurses, internists, primary care physicians, and other clinicians interested/involved in the management of patients with bladder cancer.

ESTIMATED TIME TO COMPLETE

This activity consists of 4 sessions which should take approximately 4 hours to complete.

METHOD OF PARTICIPATION

There are no fees to participate in this activity. To participate in the activity, go to www.OMedLive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

DISCLOSURE OF CONFLICTS OF INTEREST

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter Reported Financial Relationship
Neal D. Shore, MD, FACS
Medical Director, CPI
Carolina Urologic Research Center
Atlantic Urology Clinics 		Consulting Fees (e.g., advisory boards): Abbvie, Amgen, Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Boston Scientific, Clovis Oncology, Cold Genesys, Dendreon, Exact Imaging, Exact Sciences, FerGene, Foundation Medicine, Genesis Care, Invitae, Janssen, Mdchealth, Merck, Myovant, Myriad, Nymox, Pacific Edge, Pfizer, Phosphorus, Propella, PreView, Sanofi Genzyme, Specialty Networks, Sesen Bio, Tolmar, UroGen Pharma
Arjun V. Balar, MD
Associate Professor of Medicine
Director – Genitourinary Medical Oncology Program
Medical Director – Clinical Trials Office
Laura and Isaac Perlmutter Cancer Center
NYU Langone Health 		Consulting Fees (e.g., advisory boards): AstraZeneca/Medimmune, Bristol Myers Squibb, Genentech, Incyte, Istari Oncology, Janssen, Merck Nektar, Pfizer, Seagen
Fees for Non-CE Services Received Directly from an Ineligible Entity or their Agents (e.g., speakers’ bureaus): AstraZeneca/Medimmune, EpiVax Oncology, Genentech, GT Biopharma, Merck, Nektar
Contracted Research: AstraZeneca/Medimmune, Genentech, Immunomedics/Gilead, Merck, Nektar, Seagen
Equity: EpiVax Oncology, GT Biopharma
Matthew Galsky, MD
Director, Genitourinary Medical Oncology
Icahn School of Medicine at Mount Sinai Hospital
Tisch Cancer Institute 		Consulting Fees (e.g., advisory boards): AstraZeneca, Bristol Myers Squibb, EMD Serono, Genentech, Gilead, GSK, Janssen, Lilly, Merck, Pfizer, Seattle Genetics, UroGen Pharma
Contracted Research: AstraZeneca, Bristol Myers Squibb, Genentech, GSK, Merck, Seattle Genetics
John L. Gore, MD, MS
Professor
Department of Urology
University of Washington 		Contracted Research: FerGene Pharmaceuticals, Inc.
Joshua Meeks, MD, PhD
Associate Professor of Urology
Northwestern University, Feinberg School of Medicine 		Consulting Fees (e.g., advisory boards): AstraZeneca, Bristol Myers Squibb, Ferring, Foundation Medicine, Incygte, Janssen, Merck, UroGen Pharma
Contracted Research: AstraZenca, Epizyme, Genentech, Incyte, Merck
Ownership Interest greater than 5% (stocks, stock options, or other ownership interest excluding diversified mutual funds): MeshSuture
Other - Education Talks/Lectures: Olympus

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Tariqa Ackbarali
Medical Director
PlatformQ Health Education, LLC 		None

The PIM planners and managers have nothing to disclose.

The following PlatformQ Health Education, LLC planner, Jaimee Harris-Gold, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support: Please contact the Postgraduate Institute for Medicine at inquiries@pimed.com.

Technical Support: For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com.